A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer
| Autor: | Michail Ignatiadis, George Gp Stathopoulos, Anna Potamianou, Kostas Kalbakis, E. Tselepatiotis, Vassilis Georgoulias, Athanasios Kotsakis, Charalambos Christophylakis, Aris Polyzos, Lambros Vamvakas |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Pancreatic disease Phases of clinical research Docetaxel Deoxycytidine Metastasis Gefitinib Internal medicine Pancreatic cancer Antineoplastic Combined Chemotherapy Protocols medicine Humans heterocyclic compounds Epidermal growth factor receptor Neoplasm Metastasis skin and connective tissue diseases neoplasms Aged biology business.industry General Medicine Middle Aged medicine.disease Survival Analysis Gemcitabine respiratory tract diseases Surgery Pancreatic Neoplasms Quinazolines biology.protein Female Taxoids business therapeutics medicine.drug |
| Zdroj: | Oncology. 71:159-163 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000106064 |
| Popis: | Purpose: To evaluate the efficacy and tolerance of the docetaxel/gefitinib combination as second-line treatment in patients with advanced pancreatic cancer. Patients and Methods: Twenty-six patients pretreated with gemcitabine-based chemotherapy were enrolled in the study. Docetaxel (75 mg/m2, i.v.) was administered every 3 weeks for a maximum of 6 cycles and gefitinib (250 mg/day, p.o.) was given continuously. Results: Five (19.2%) patients achieved stable disease. The median duration of disease control was 4.8 months (range 1–13.2), the median time to disease progression 2.1 months (range 1–7.3) and the median survival time 2.9 months (range 1–13.9). Grade 3/4 neutropenia was recorded in 9 (34.6%) patients, although only 1 (3.8%) developed grade 2 febrile neutropenia. One (3.8%) patient experienced grade 3 fatigue and 2 (7.7%) grade 3 diarrhea. Grade 1/2 rash was observed in 13 (50%) patients. There were no treatment-related deaths. Conclusion: The docetaxel/gefitinib combination, although safe, has no activity as salvage treatment for advanced pancreatic cancer after failure of gemcitabine-based chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|